Search

Search Results

1. Dosimetry and pharmacokinetics of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours

   Purpose

   To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [ ¹⁷⁷ Lu]Lu-satoreotide tetraxetan...

   Seval Beykan Schürrle, Uta Eberlein, ... Michael Lassmann in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 26 March 2024
   

2. A phase I/II study of the safety and efficacy of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

   Purpose

   We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR)...

   Damian Wild, Henning Grønbæk, ... Rodney J. Hicks in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 18 September 2023
   

3. Comparison of ⁶⁸Ga-DOTA-JR11 PET/CT with dosimetric ¹⁷⁷Lu-satoreotide tetraxetan (¹⁷⁷Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy

   Purpose

   Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim...

   Simone Krebs, Joseph A. O’Donoghue, ... Neeta Pandit-Taskar in European Journal of Nuclear Medicine and Molecular Imaging

   Article 06 May 2020
   

4. Relationships between uptake of [⁶⁸Ga]Ga-DOTA-TATE and absorbed dose in [¹⁷⁷Lu]Lu-DOTA-TATE therapy

   Background

   Somatostatin receptor ⁶⁸ Ga PET imaging is standard for evaluation of a patient’s suitability for ¹⁷⁷ Lu peptide receptor radionuclide...

   Anna Stenvall, Johan Gustafsson, ... Katarina Sjögreen Gleisner in EJNMMI Research

   Article Open access 19 December 2022
   

5. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

   The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry....

   Katarina Sjögreen Gleisner, Nicolas Chouin, ... Jonathan Gear in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 14 March 2022
   

6. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities

   Neuroendocrine tumors (NETs) are a heterogenous group of neoplasms characterized by varied biological hallmarks and behavior, ranging from indolent...

   Shagufta Shaheen, Farshad Moradi, ... Pamela L. Kunz in Current Treatment Options in Oncology

   Article 14 March 2020

7. EANM’23 Abstract Book Congress Sep 9-13, 2023

   in European Journal of Nuclear Medicine and Molecular Imaging

   Article 18 August 2023

8. European Association of Nuclear Medicine October 22 – 30, 2020 Virtual

   in European Journal of Nuclear Medicine and Molecular Imaging

   Article 18 September 2020

9. World Molecular Imaging Congress 2022

   in Molecular Imaging and Biology

   Article 01 December 2022